StreetInsider.com News Articles

TD Cowen Starts Kalaris (KLRS) at Buy

Mon, 15 Jun 2026 05:32:01 -0400

TD Cowen analyst Tara Bancroft initiates coverage on Kalaris (NASDAQ: KLRS) with a Buy rating.

The analyst comments "TH103 is a differentiated anti-VEGF by design through more potent VEGF inhibition and retinal retention. Early data in wAMD suggest even a single dose can achieve competitive efficacy vs. SOC anti-VEGFs, leaving space for further differentiation via repeat dosing. Preliminary durability suggests potential for less frequent dosing - a key driver of adoption in a large $15B market. Initiate at Buy."

For an analyst ratings summary and ratings history on Kalaris click here. For more ratings news on Kalaris click here.

Shares of

TD Cowen Starts Kalaris (KLRS) at Buy

Mon, 15 Jun 2026 05:32:01 -0400

TD Cowen analyst Tara Bancroft initiates coverage on Kalaris (NASDAQ: KLRS) with a Buy rating.

For an analyst ratings summary and ratings history on Kalaris click here. For more ratings news on Kalaris click here.

Shares of

Kalaris to Present at Clinical Trials at the Summit 2026

Fri, 12 Jun 2026 08:00:00 -0400

BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026. The presentation will feature single ascending dose results from treatment-naïve patients with Neovascular Age-Related Macular Degeneration (AMD) — one of the leading causes of vision loss worldwide. These data were recently presented at Retina World Congress 2026.

Details:

Title: First-in-Human Trial of TH103: A

Kalaris to Present at Clinical Trials at the Summit 2026

Fri, 12 Jun 2026 08:00:00 -0400

Details:

Title: First-in-Human Trial of TH103: A

Kalaris to Present at Clinical Trials at the Summit 2026

Fri, 12 Jun 2026 08:00:00 -0400

Details:

Title: First-in-Human Trial of TH103: A

Kalaris to Present at Clinical Trials at the Summit 2026

Fri, 12 Jun 2026 08:00:00 -0400

Details:

Title: First-in-Human Trial of TH103: A

Kalaris to Present at Clinical Trials at the Summit 2026

Fri, 12 Jun 2026 08:00:00 -0400

Details:

Title: First-in-Human Trial of TH103: A

Kalaris to Present at Clinical Trials at the Summit 2026

Fri, 12 Jun 2026 08:00:00 -0400

Details:

Title: First-in-Human Trial of TH103: A

Kalaris to Present at Clinical Trials at the Summit 2026

Fri, 12 Jun 2026 08:00:00 -0400

Details:

Title: First-in-Human Trial of TH103: A

Kalaris to Present at Clinical Trials at the Summit 2026

Fri, 12 Jun 2026 08:00:00 -0400

Details:

Title: First-in-Human Trial of TH103: A

Wedbush Starts Kalaris (KLRS) at Outperform

Thu, 14 May 2026 06:53:24 -0400

Wedbush analyst Yun Zhong initiates coverage on Kalaris (NASDAQ: KLRS) with a Outperform rating and a price target of $17.00.

For an analyst ratings summary and ratings history on Kalaris click here. For more ratings news on Kalaris click here.

Shares of Kalaris closed at $4.83 yesterday.

Kalaris (KLRS) PT Lowered to $25 at Citizens Ahead of Phase 1b/2 MAD data in 2027

Wed, 13 May 2026 05:08:37 -0400

Citizens analyst Jonathan Wolleben lowered the price target on Kalaris (NASDAQ: KLRS) to $25.00 (from $26.00) while maintaining a Market Outperform rating.

The analyst commented, "Importantly, KLRS completed its manufacturing process enhancements that have further reduced already low levels of process impurities suspected of being the cause of intraocular inflammation (IOI) observed in the Phase 1a trial. We are looking forward to the Phase 1b/2 MAD data in 1H27 to confirm TH103’s safety and impressive early efficacy signal. Recall, single doses of TH103 led to a mean 10-letter improvement and 129 um reduction in CST. Furthermore, 31% of patients lasted six

Kalaris (KLRS) PT Lowered to $25 at Citizens Ahead of Phase 1b/2 MAD data in 2027

Wed, 13 May 2026 05:08:37 -0400

Citizens analyst Jonathan Wolleben lowered the price target on Kalaris (NASDAQ: KLRS) to $25.00 (from $26.00) while maintaining a Market Outperform rating.

Kalaris Therapeutics (KLRS) Misses Q1 EPS by 46c

Tue, 12 May 2026 16:26:38 -0400

Kalaris Therapeutics (NASDAQ: KLRS) reported Q1 EPS of ($0.46).

For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.

Raymond James on Kalaris (KLRS): 'We continue to expect Kalaris to resume dosing in 2Q26 '

Tue, 12 May 2026 12:21:06 -0400

Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $23.00 price target on Kalaris (NASDAQ: KLRS).

The analyst comments "Remain Strong Buy rated on KLRS shares following this morning’s 1Q26 update. Today Kalaris highlighted that patient screening in the P1b/2 trial is underway and expects to resume dosing after the latest batch of TH103 finishes packaging and labeling. Recall that Kalaris paused enrollment and dosing in the P1b/2 trial after cases of intraocular inflammation (IOI) were observed at the 5 mg SAD and 1.5 mg MAD cohort. Kalaris identified that the IOI cases were due to host cell protein

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 08:00:00 -0400

Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027

Planned Phase 3 clinical trials remain on track for 2027 year-end initiation